Atriva Therapeutics' Seed VC - II Round

Atriva Therapeutics raised a round of funding on September 22, 2017.

Atriva Therapeutics develops antiviral therapies. Atriva's product platform draws from selected repurposed MEK kinase inhibitors and focuses on acute viral infections like influenza, RSV or MERS.…

Articles about Atriva Therapeutics' Seed VC - II Round: